5th Bacteriophage Therapy Summit

Explore significant advancements in clinical trial design to push medicinal phage therapies to the clinic, CRISPR-based gene editing to improve functionality, the rise of lytic technologies, and alternative potential for phage technologies beyond human health. This is the conference of the year for biopharma, clinicians and consumer product developers to harness the safety and efficacy of phages.

Whether you're at the forefront of the field or emerging into phage therapy for the first time, the 5th Bacteriophage Therapy Summit is the key networking platform that enables you to meaningfully apply phage science and prove commercial success.

URLs:
Website: https://go.evvnt.com/1387351-0?pid=10018
Tickets: https://go.evvnt.com/1387351-2?pid=10018
Brochure: https://go.evvnt.com/1387351-3?pid=10018

Prices:
Industry Rate - Conference Only: USD 2099.00,
Industry Rate - Conference + 1 Workshop : USD 2498.00,
Industry Rate - Conference + 2 Workshops: USD 2897.00,
Academic - Conference Only : USD 1599.00,
Academic - Conference + 1 Workshop: USD 1798.00,
Academic - Conference + 2 Workshops : USD 1997.00

Speakers: Bob Blasdel, Director - Research, Vesale Pharma , Danish Malik, Reader Industrial Biology, Loughborough University, Edward Burd, Senior Vice President Regulatory Affairs, BiomX, Iddo Nadav Weiner, Director and Head of Software, BiomX, Lorenzo Corsini, Co-Founder and Chief Executive Officer, Phagomed, Minmin Yen, Chief Executive Officer and Co-Founder, PhagePro, Vincent Fischetti, Professor and Head of Lab, The Rockefeller University Viviana Clavijo, Chief Executive Officer, Sciphage, Clara Leandro, Head of Infection, TechnoPhage SA, David Harper, Chief Executive Officer. Evolution Biotechnologies, Jakob Krause Haaber, Vice President and Head Of Delivery Technologies, CRISPR Therapeutics, Joël van Mierlo, R&D Manager, Micreos Food Safety, Joseph Campbell, Research Resources Section and Program Officer, National Institute of Health Science, Justyna Kowalska, Head of Product Management, Proteon Pharmaceuticals, Viviana Clavijo, Director, Chief Executive and Technology Officer, SciPhage, Mark Connelly, Clinical Reviewer, US Food and Drug Administration (FDA), Matjaz Peterka, Chief Executive Officer, COBIK, Michele Wales, Chief Legal Officer, Adaptive Phage Therapeutics Inc., Nancy Tawil, Chief Scientific Officer, Phagelux Inc., Panagiota Tzani-Tzanopoulou, Medical Science Liaison, Allergy and Clinical Immunology Unit, P&A Kyriakou Hospital, Tiina Orasmae-Meder, Founder and director, Meder Beauty International Ltd